Triple negative breast cancer is an aggressive subtype with a higher recurrence and mortality rate than other subtypes. For standard treatment of early stage II-III (high risk), neoadjuvant multi-agent chemotherapy based on anthracyclines and taxanes, often with carboplatin, followed by surgery is preferred. The phase 3 CITRINE trial investigated the addition of carboplatin to standard adjuvant anthracycline-taxane chemotherapy in patients after surgery. The study enrolled 808 Chinese women with high-risk early triple-negative breast cancer. The addition of carboplatin improved three-year disease-free survival by 6.5% absolute (92.3% versus 85.8%). Overall survival was also improved by 4% absolute (98.0% versus 94.0%). These findings represent an advance in adjuvant therapy.